Xponance Inc. Increases Position in Enovis Co. (NYSE:ENOV)

Xponance Inc. increased its position in Enovis Co. (NYSE:ENOV) by 7.8% in the fourth quarter, HoldingsChannel.com reports. The fund owned 6,380 shares of the company’s stock after buying an additional 462 shares during the period. Xponance Inc.’s holdings in Enovis were worth $280,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Boston Partners raised its stake in shares of Enovis by 27.1% in the fourth quarter. Boston Partners now owns 1,048,532 shares of the company’s stock worth $46,034,000 after purchasing an additional 223,816 shares during the last quarter. Royce & Associates LP increased its holdings in Enovis by 2.8% in the 4th quarter. Royce & Associates LP now owns 2,470,576 shares of the company’s stock worth $108,409,000 after buying an additional 66,891 shares during the period. Envestnet Portfolio Solutions Inc. lifted its stake in Enovis by 19.5% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 15,433 shares of the company’s stock valued at $677,000 after acquiring an additional 2,518 shares during the period. Natixis Advisors LLC boosted its holdings in shares of Enovis by 52.8% in the 4th quarter. Natixis Advisors LLC now owns 19,381 shares of the company’s stock valued at $850,000 after acquiring an additional 6,701 shares during the last quarter. Finally, Ironwood Investment Management LLC increased its stake in shares of Enovis by 4.0% in the fourth quarter. Ironwood Investment Management LLC now owns 14,155 shares of the company’s stock worth $621,000 after acquiring an additional 545 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC cut their price target on Enovis from $65.00 to $64.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th.

Enovis Price Performance

NYSE:ENOV opened at $38.89 on Friday. The company has a 50 day moving average price of $42.24 and a 200-day moving average price of $43.38. Enovis Co. has a 1-year low of $35.14 and a 1-year high of $62.79. The firm has a market cap of $2.22 billion, a price-to-earnings ratio of -17.76 and a beta of 2.05. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12.

Enovis (NYSE:ENOV) last issued its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.06. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The business had revenue of $560.98 million during the quarter, compared to the consensus estimate of $555.14 million. Equities research analysts forecast that Enovis Co. will post 2.79 EPS for the current year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.